On MONDAY, PhaseBio Pharmaceuticals, Inc. (NASDAQ: PHAS) spotted trading -76.28% off 52-week high price. On the other end, the stock has been noted 54.90% away from the low price over the last 52-weeks. The stock changed -5.05% to recent value of $3.95. The stock transacted 138982 shares during most recent day however it has an average volume of 314.2K shares. The company has 28.15M of outstanding shares and 22.97M shares were floated in the market.
PhaseBio Pharmaceuticals, Inc. (PHAS) recently reported that the first patient has been dosed in a Phase 2b clinical trial of PB2452, a novel, recombinant, human monoclonal antibody antigen-binding fragment designed to reverse the antiplatelet activity of ticagrelor in major bleeding and urgent surgery situations.
“We are happy that the first patient has been dosed in the registrational Phase 2b clinical trial of PB2452, as it signifies continued progress on our Accelerated Authorization pathway discussed with the FDA at our End-of-Phase 1 meeting,” stated John Lee, M.D., Ph.D., Chief Medical Officer of PhaseBio. “We continue to be encouraged by the potential of PB2452 to address a important unmet need for patients by reversing the antiplatelet activity of ticagrelor in major bleeding and urgent surgery situations. Our plans to initiate our Phase 3 trial in the first quarter of 2020 and potentially submit a BLA for PB2452 in the second half of 2022 remain on track.”
PhaseBio Pharmaceuticals, IncIts earnings per share (EPS) expected to touch remained -86.10% for this year. According to the most recent quarter its current ratio was 16.5 that represents company’s ability to meet its current financial obligations. The price moved ahead of -9.48% from the mean of 20 days, -35.17% from mean of 50 days SMA and performed -49.67% from mean of 200 days price. Company’s performance for the week was -5.28%, -26.44% for month and YTD performance remained 27.83%.